Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €56.71 EUR
Change Today -0.90 / -1.57%
Volume 1.1M
As of 11:45 AM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

fresenius se & co kgaa (FRE) Snapshot

Open
€57.22
Previous Close
€57.61
Day High
€57.91
Day Low
€56.66
52 Week High
05/26/15 - €57.91
52 Week Low
08/15/14 - €35.10
Market Cap
30.8B
Average Volume 10 Days
935.6K
EPS TTM
€2.09
Shares Outstanding
542.9M
EX-Date
05/21/15
P/E TM
27.2x
Dividend
€0.44
Dividend Yield
0.77%
Current Stock Chart for FRESENIUS SE & CO KGAA (FRE)

Related News

No related news articles were found.

fresenius se & co kgaa (FRE) Related Businessweek News

No Related Businessweek News Found

fresenius se & co kgaa (FRE) Details

Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment provides products for hemodialysis and peritoneal dialysis. This segment offers dialyzers, dialysis machines, and renal pharmaceuticals, as well as dialysis- related services. As of December 31, 2014, it treated approximately 285,312 patients at 3,361 dialysis clinics. The Fresenius Kabi segment provides therapy and care for chronically and critically ill patients. This segment offers intravenously administered generic drugs, such as anesthetics, anti-infectives, and analgesics, as well as drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps; products used in the collection and processing whole blood and blood components, as well as in transfusion medicine. The Fresenius Helios segment operated approximately 110 hospitals, including 86 acute care hospitals and 24 post acute care clinics; 47 outpatient clinics; and 15 nursing homes. The Fresenius Vamed manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as provides maintenance, technical, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg, Germany.

217,836 Employees
Last Reported Date: 05/6/15
Founded in 1912

fresenius se & co kgaa (FRE) Top Compensated Officers

Chairman of the Management Board - Fresenius ...
Total Annual Compensation: €2.4M
Chief Financial Officer of Fresenius Manageme...
Total Annual Compensation: €1.5M
Chief Legal & Compliance Officer of Fresenius...
Total Annual Compensation: €1.1M
Member of Management Board - Fresenius Manage...
Total Annual Compensation: €2.9M
Member of Management Board - Fresenius Manage...
Total Annual Compensation: €1.6M
Compensation as of Fiscal Year 2014.

fresenius se & co kgaa (FRE) Key Developments

Fresenius SE & Co KGaA - Shareholder/Analyst Call

Annual general meeting 2015

Fresenius SE & Co KGaA Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Raises Earnings Guidance for the Full Year of 2015

Fresenius SE & Co KGaA announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported sales of EUR 6,578 million compared to EUR 5,258 million a year ago. Operating income was EUR 872 million compared to EUR 651 million a year ago. Income before income taxes was EUR 707 million compared to EUR 513 million a year ago. Net income was EUR 503 million compared to EUR 377 million a year ago. Net income attributable to shareholders of the company was EUR 314 million compared to EUR 243 million a year ago. Fully diluted earnings per ordinary share in (after stock split 1:3) were EUR 0.58 compared to EUR 0.45 a year ago. Net cash provided by operating activities was EUR 534 million compared to EUR 142 million a year ago. Purchase of property, plant and equipment was EUR 282 million compared to EUR 248 million a year ago. As of March 31, 2015, the company reported net debt was EUR 14,841 million. Net capital expenditure increased to EUR 276 million compared to EUR 245 million for the same period a year ago. EBIT was EUR 854 million compared to EUR 630 million a year ago. Group EBIT was EUR 872 million compared to EUR 651 million a year ago. EBITDA was EUR 1,140 million compared to EUR 878 million a year ago. The company raised earnings guidance for the full year of 2015. For 2015, the company expects net income growth of 13% to 16% in constant currency. Previously, the company expected net income growth of 9% to 12% in constant currency. Sales are expected to increase by 7% to 10% in constant currency.

Fresenius Reports Earnings Results for the First Quarter of 2015

Fresenius reported earnings results for the first quarter of 2015. For the period, the company achieved sales of EUR 6,483,000,000, EBITDA of EUR 851 million and net income of EUR 292 million. The absolute level of sales and net income and the solid double-digit growth rates in constant currency and actual currency rates made this one of most successful quarters ever. EBIT reached EUR 851 million, up 18% year-on-year at constant currency. Net income reached EUR 292 million, so 16% increase at constant currency.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FRE:GR €56.71 EUR -0.90

FRE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FRE.
View Industry Companies
 

Industry Analysis

FRE

Industry Average

Valuation FRE Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FRESENIUS SE & CO KGAA, please visit www.fresenius.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.